5-Amino-1MQ Half-Life

The Pharmacokinetic Knowledge Gap: What We Don't Know

5-Amino-1MQ remains a research chemical with incomplete pharmacokinetic characterization in humans. While the compound has been used in preclinical studies and appears in early human research contexts, a complete pharmacokinetic profile—including elimination half-life, bioavailability, absorption kinetics, tissue distribution, and metabolic pathways—has not been published in peer-reviewed literature. This represents a critical gap in understanding how the compound behaves in the human body and has important implications for dosing protocols, timing, and efficacy predictions.

The absence of half-life data creates a practical problem: dosing recommendations are inferred from mechanism of action and preclinical observations rather than human pharmacokinetic studies. Standard recommendations (150-500 mcg subcutaneous or 50-100 mg oral, once to twice daily) assume that NNMT inhibition effect duration supports daily or twice-daily dosing, but direct evidence for optimal dosing interval remains absent. Researchers and users are essentially making educated guesses based on similar compounds and theoretical NNMT dynamics.

Despite these limitations, some extrapolation is possible from preclinical data and from knowledge of NNMT pharmacology. Understanding what we know about 5-Amino-1MQ's likely pharmacokinetics—and acknowledging what remains unknown—allows users to make informed decisions about dosing, timing, and monitoring.

Preclinical Pharmacokinetic Data and Animal Studies

Preclinical studies of 5-Amino-1MQ in rodent models suggest a relatively short half-life and rapid tissue distribution. In mouse and rat models, the compound appears to be absorbed quickly from subcutaneous or oral administration, distributes rapidly to target tissues (particularly adipose tissue and liver where NNMT is highly expressed), and is eliminated relatively rapidly. Peak plasma concentrations likely occur within 15-30 minutes of subcutaneous injection or within 30-60 minutes of oral administration, though specific timing data is not published.

The apparent short half-life in preclinical models suggests 5-Amino-1MQ is likely metabolized hepatically (through phase I and/or phase II metabolism) and rapidly cleared, necessitating frequent dosing to maintain steady-state NNMT inhibition. This contrasts with some other peptides or small molecules that have half-lives measured in hours or days; 5-Amino-1MQ's apparent short half-life more resembles compounds like caffeine (5-6 hour half-life) or acute sympathomimetics, where multiple daily doses are required for sustained effect.

However, it is crucial to emphasize that animal pharmacokinetics do not directly predict human pharmacokinetics. Species differences in drug metabolism, clearance, and distribution are substantial. Human hepatic metabolism may be faster or slower than rodent metabolism depending on specific CYP450 enzyme expression and function. Plasma protein binding, tissue distribution, and metabolic pathways may differ significantly between animals and humans. Therefore, preclinical half-life estimates should be viewed as rough guides only, not definitive predictions for human use.

Bioavailability by Route of Administration

5-Amino-1MQ can theoretically be administered via multiple routes: subcutaneous injection, intramuscular injection, intravenous injection, oral, intranasal, or other routes. Each route produces different absorption kinetics, peak plasma concentrations, and bioavailability. Bioavailability refers to the percentage of administered dose that reaches systemic circulation in active form.

Subcutaneous Administration: Subcutaneous injection (the most commonly discussed administration route in research contexts) provides relatively rapid absorption with peak plasma concentrations estimated within 15-30 minutes. Bioavailability is typically near 100% for subcutaneous injection, as the compound is delivered directly into tissue with high local blood supply, bypassing first-pass hepatic metabolism. This makes subcutaneous administration the most efficient route in terms of achieving desired plasma concentrations with the smallest dose. The sustained-release depot effect sometimes seen with subcutaneous peptide administration is unlikely for 5-Amino-1MQ given its apparent short half-life; the compound likely distributes rapidly and is cleared within hours.

Oral Administration: Oral bioavailability of 5-Amino-1MQ is unknown but likely reduced compared to subcutaneous administration due to first-pass hepatic metabolism and potential degradation in the gastrointestinal tract. Small molecule NNMT inhibitors in preclinical development typically show 20-60% oral bioavailability, suggesting 5-Amino-1MQ oral bioavailability may fall in this range. If oral bioavailability is 30-40%, then achieving equivalent systemic exposure via oral route would require 2-3 times higher oral dose compared to subcutaneous dose. This explains why oral 5-Amino-1MQ recommendations typically specify 50-100 mg oral (compared to 150-500 mcg subcutaneous)—the oral dose must be substantially higher to compensate for reduced absorption.

Other Routes: Intramuscular administration would likely produce bioavailability and absorption kinetics similar to subcutaneous, perhaps with slightly slower absorption due to intramuscular depot formation. Intravenous administration would provide 100% bioavailability with immediate peak concentrations, but is impractical for sustained NNMT inhibition given the apparent short half-life. Intranasal administration is theoretical and lacks any supporting data.

Absorption Kinetics and Time-to-Peak Concentration

Understanding absorption kinetics—the rate and extent of drug entry into the bloodstream—is important for timing 5-Amino-1MQ administration relative to meals, training, or other activities intended to benefit from NNMT inhibition. While precise human absorption kinetics are unknown, reasonable inferences can be made from preclinical data and compound characteristics.

Subcutaneous Administration: Subcutaneous injection produces absorption kinetics dependent on local blood flow, injection site, and subcutaneous depot formation. For rapidly absorbed small molecules, subcutaneous Tmax (time to peak plasma concentration) typically ranges from 15-45 minutes. 5-Amino-1MQ, given its apparent rapid tissue penetration observed in animal models, likely achieves peak concentrations within 20-30 minutes of subcutaneous injection. This relatively rapid Tmax suggests that subcutaneous injection 30 minutes before intended metabolic activity (fasted training, morning cardio) could time peak compound bioavailability with peak metabolic demand, potentially optimizing fat oxidation during exercise.

Oral Administration: Oral absorption depends on gastrointestinal pH, food intake, gastrointestinal motility, and intestinal permeability. For small molecule compounds, Tmax typically ranges from 30 minutes to 2 hours. 5-Amino-1MQ oral Tmax is unknown but likely falls in the 45-120 minute range. Taking oral 5-Amino-1MQ on an empty stomach in the morning might produce peak bioavailability within 1 hour, ideally timed before morning fasted cardio or training. Food, particularly high-fat meals, might delay or reduce absorption; consistent timing relative to meals is important for maintaining steady absorption kinetics and predictable plasma concentrations.

Tissue Distribution and Target Tissue Accumulation

5-Amino-1MQ's primary mechanism—NNMT inhibition—requires the compound to reach target tissues where NNMT is highly expressed. Adipose tissue (brown and white), liver, kidney, and skeletal muscle are primary NNMT-expressing tissues. The compound must cross cell membranes and achieve intracellular concentrations sufficient to inhibit NNMT enzyme. Preclinical evidence suggests the compound distributes readily to these target tissues, achieving concentrations sufficient for NNMT inhibition, but specific tissue distribution volumes and tissue:plasma concentration ratios are unpublished.

Rapid distribution to target tissues is desirable for achieving NNMT inhibition effect, but raises questions about compound clearance from tissues. If 5-Amino-1MQ distributes widely and accumulates in target tissues but has a short plasma half-life, intracellular or tissue-bound compound might persist longer than circulating compound. This would mean NNMT inhibition continues even as plasma concentrations decline, potentially extending the duration of effect beyond what plasma half-life alone would predict. Alternatively, if the compound is rapidly cleared from tissues as well, the duration of NNMT inhibition might be quite short, requiring frequent dosing for sustained effect.

The tissue distribution patterns also have safety implications. High concentrations in hepatic tissue could theoretically increase risk of hepatotoxicity; accumulation in renal tissue could affect kidney function. However, preclinical safety studies (referenced in early literature) did not identify hepatic or renal toxicity at doses used, suggesting either limited tissue accumulation or that tissue concentrations remain within a safe range.

Metabolism Pathways and Drug Interactions

The metabolic fate of 5-Amino-1MQ—how it is broken down and eliminated—remains incompletely characterized. As a small molecule synthesized compound (5-Amino-1-Methyl-Quinolinium), it is likely metabolized hepatically via cytochrome P450 enzymes (particularly CYP3A4, CYP2C19, or CYP2D6) and/or phase II conjugation enzymes (glucuronidation, sulfation). The metabolic byproducts are likely excreted in urine and bile, but specific metabolites and their activities are unknown.

This uncertainty about metabolic pathways has important implications for drug interactions. If 5-Amino-1MQ is metabolized primarily by CYP3A4, concurrent use of CYP3A4 inhibitors (ketoconazole, ritonavir, grapefruit juice, certain statins) could reduce 5-Amino-1MQ clearance and increase plasma concentrations. Conversely, CYP3A4 inducers (rifampin, carbamazepine, phenytoin) could increase clearance and reduce effectiveness. Similarly, competition for hepatic metabolism pathways or for renal excretion with other medications could alter 5-Amino-1MQ kinetics.

Without knowing the specific metabolic pathways, users cannot definitively predict drug interactions. Conservatively, men and women using 5-Amino-1MQ should inform healthcare providers of concurrent medications and understand that unexpected metabolic interactions are possible. If using 5-Amino-1MQ alongside medications affecting liver function or hepatic metabolism, periodic liver function monitoring is prudent.

Steady-State Kinetics and Accumulation Potential

Steady-state is achieved when the rate of drug administration equals the rate of drug elimination, resulting in relatively stable plasma concentrations that fluctuate minimally between doses. For compounds dosed once or twice daily, steady-state is typically achieved within 3-5 half-lives of consistent dosing. If 5-Amino-1MQ has a short half-life (estimated 1-2 hours or less based on preclinical data), steady-state would be achieved within 3-10 hours of first dose—meaning consistent dosing (even once daily) could produce steady-state NNMT inhibition within a single day.

The short estimated half-life suggests minimal drug accumulation with repeated dosing. Some medications with longer half-lives accumulate substantially with repeated dosing; a drug with a 10-hour half-life dosed twice daily could accumulate 1.5-2 times the single-dose concentration. If 5-Amino-1MQ has a 1-2 hour half-life, accumulation with standard twice-daily dosing would be minimal—each dose is largely eliminated before the next dose is administered. This suggests that 5-Amino-1MQ toxicity risk from accumulation is low, but also that missing a dose immediately reduces compound bioavailability and NNMT inhibition effect.

What Happens When You Miss a Dose

Given the assumed short half-life of 5-Amino-1MQ, missing a single dose likely results in rapid decline of plasma concentrations and loss of NNMT inhibition effect within 2-4 hours of the intended dosing time. This means if 5-Amino-1MQ is dosed twice daily (morning and evening), missing the morning dose eliminates NNMT inhibition for most of the day; the evening dose would begin re-establishing inhibition but would be insufficient to maintain 24-hour coverage.

The practical consequence is that 5-Amino-1MQ efficacy is highly dependent on dosing consistency. Missing doses, delaying doses, or inconsistent timing likely reduces efficacy significantly. This contrasts with longer-acting compounds (those with 8-12 hour or longer half-lives) where occasional missed doses produce minimal efficacy loss. For 5-Amino-1MQ users, setting phone alarms or reminders for consistent dosing intervals is advisable to maintain steady NNMT inhibition and metabolic effects.

If a dose is missed, the best practice is to resume the normal dosing schedule at the next scheduled time. Do not double-dose to compensate for a missed dose; doubling risks temporary toxicity. If dosing is frequently inconsistent or missed, efficacy is likely compromised and reassessment of the feasibility of maintaining a consistent dosing regimen is warranted.

Comparison to Other NNMT Inhibitors and NAD+ Boosting Compounds

Several other NNMT inhibitors and NAD+-boosting compounds exist in research and clinical contexts, offering pharmacokinetic comparisons that contextualize 5-Amino-1MQ's likely characteristics. Understanding how 5-Amino-1MQ differs pharmacokinetically from related compounds helps users understand its positioning in the broader pharmacological landscape.

NAD+ Precursors (NMN, NR, NA): NAD+ precursors like nicotinamide mononucleotide (NMN) or nicotinamide riboside (NR) have very short half-lives (minutes to hours in some cases) and are not well absorbed orally. They must be administered frequently (often twice daily) for sustained NAD+ elevation. 5-Amino-1MQ, working through NNMT inhibition rather than direct NAD+ precursor provision, may provide more sustained NNMT inhibition than NAD+ precursor supplementation provides direct NAD+ elevation, assuming NNMT inhibition persists longer than NAD+ precursor elevation.

Other Small Molecule NNMT Inhibitors: Several pharmaceutical companies have developed small molecule NNMT inhibitors for metabolic and oncologic indications. Published pharmacokinetic data for these compounds (not yet named 5-Amino-1MQ in some cases) suggests half-lives in the 1-4 hour range and oral bioavailability of 20-60%, consistent with theoretical predictions for 5-Amino-1MQ. This suggests 5-Amino-1MQ's pharmacokinetics are likely typical of small molecule NNMT inhibitors, requiring multiple daily doses for sustained NNMT inhibition.

Nicotinamide Adenine Dinucleotide (NAD+) Directly: Intravenous NAD+ infusions (used in some clinical contexts) bypass the need for precursors or inhibitors, providing direct NAD+ elevation. However, NAD+ has an extremely short half-life (seconds to minutes), necessitating continuous infusion for sustained elevation. Oral NAD+ is essentially ineffective due to rapid degradation. This illustrates why NNMT inhibition (working upstream to restore NAD+ synthesis) may offer advantages over direct NAD+ supplementation for achieving sustained metabolic effects.

Trusted Research-Grade Sources

Below are the two vendors we recommend for research peptides — both publish independent third-party Certificates of Analysis (COAs) and ship internationally. Affiliate links: we earn a small commission at no extra cost to you (see Affiliate Disclosure).

Frequently Asked Questions